SII will buy 20 percent stake in Integrimedical
New Delhi, Vaccine maker Serum Institute of India (SII) on Friday said it is acquiring 20 per cent stake in Integrimedical to advance needle-free injection system technology.
IntegriMedical has developed a US-patented needle-free injection system (N-FIS)
that uses mechanical power to effectively administer biologics and drugs
through high-speed injection, Serum Institute of India (SII) said in a
statement. Velocity uses the jet stream.
However, the company did not disclose financial details of the transaction.
The innovative drug delivery solution aims to minimize pain during
administration, providing a stress-free experience to needle-phobic patients.
“IntegriMedical's N-FIS represents a significant advancement in drug delivery
and we envision a needle-free solution for delivering vaccines. We believe this
could potentially revolutionize the way we administer vaccines, making the
process more comfortable for patients and health care professionals,” said SII
CE Adar Poonawala.
IntegriMedical's N-FIS has received regulatory approvals from CDSCO (Centra
Drugs Standard Control Organisation), CE (European Regulatory Approvals), MDSA
(Medical Device Single Audit Programme, Australia) and is ISO 13485 certified,
the statement said.
Comments
Post a Comment